Carboplatin + Mirvetuximab Soravtansine for Ovarian Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new combination of treatments for advanced ovarian cancer, specifically targeting tumors with the protein folate receptor alpha (FRα). The trial aims to assess the safety and effectiveness of carboplatin and an investigational drug, mirvetuximab soravtansine (a type of targeted therapy), when used together before surgery. Participants will receive these drugs through an IV every three weeks. Suitable candidates have advanced-stage ovarian cancer with high FRα expression and have not undergone significant prior cancer treatments. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group of people.
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.
Is there any evidence suggesting that this treatment is likely to be safe for humans?
Research has shown that combining carboplatin and mirvetuximab soravtansine is generally safe for patients. In earlier studies, this treatment effectively targeted cancer and did not cause serious side effects for most individuals. Some patients experienced mild to moderate side effects, which were usually manageable. These results from previous studies provide insight into the treatment's safety. However, as this is a Phase 2 trial, the researchers are still testing to learn more about the treatment's safety and effectiveness.12345
Why do researchers think this study treatment might be promising for ovarian cancer?
Researchers are excited about the combination of carboplatin and mirvetuximab soravtansine for treating ovarian cancer because of its unique approach. Unlike standard treatments that rely solely on chemotherapy, mirvetuximab soravtansine is an antibody-drug conjugate that targets and delivers a potent anti-tumor agent directly to cancer cells, minimizing damage to healthy cells. This targeted delivery could enhance the effectiveness of carboplatin while potentially reducing side effects, offering a promising new option for patients.
What evidence suggests that this treatment might be an effective treatment for ovarian cancer?
Studies have shown that using carboplatin with mirvetuximab soravtansine holds promise for treating certain types of ovarian cancer. Research indicates that these drugs work well together, especially when cancer cells have a specific protein called folate receptor alpha (FRα). In earlier trials, about 71% of patients with this type of cancer responded positively to the treatment. The combination demonstrated strong anti-tumor activity, effectively shrinking or controlling cancer growth. This evidence suggests that carboplatin and mirvetuximab soravtansine could be an effective option for those with FRα-positive ovarian cancer. Participants in this trial will receive this combination treatment to further evaluate its effectiveness.14678
Who Is on the Research Team?
ABBVIE INC.
Principal Investigator
AbbVie
Are You a Good Fit for This Trial?
This trial is for adults with advanced-stage serous epithelial ovarian, fallopian tube, or primary peritoneal cancer that expresses a protein called folate receptor alpha (FRα). Participants must have measurable disease, be in good physical condition (ECOG 0-1), and be suitable candidates for neoadjuvant chemotherapy.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive intravenous infusion of MIRV in combination with carboplatin on day 1 of each cycle, every 21 days for up to 6 - 9 cycles
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Carboplatin
- Mirvetuximab Soravtansine
Trial Overview
The study tests the combination of Carboplatin and Mirvetuximab Soravtansine given through IV every three weeks for up to six to nine cycles. It aims to assess safety and effectiveness in killing cancer cells by targeting FRα. The trial will enroll around 140 participants over approximately three years.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Participants will receive carboplatin in combination with mirvetuximab soravtansine on Day 1 of a 21-day cycle per dose +/- Bevacizumab per investigator's discretion.
Find a Clinic Near You
Who Is Running the Clinical Trial?
AbbVie
Lead Sponsor
Dr. Roopal Thakkar
AbbVie
Chief Medical Officer since 2023
MD from Wayne State University School of Medicine
Robert A. Michael
AbbVie
Chief Executive Officer
Bachelor's degree in Finance from the University of Illinois
GOG Foundation
Collaborator
Citations
Phase 1b study of mirvetuximab soravtansine, a folate ...
The efficacy outcomes observed with this mirvetuximab soravtansine plus carboplatin and bevacizumab triplet regimen are promising compared with those ...
Study Details | nct05456685 | Mirvetuximab Soravtansine ...
This Phase 2 study is designed to evaluate the efficacy and safety of MIRV in combination with carboplatin followed by MIRV continuation in FRα-positive ...
3.
international-journal-of-gynecological-cancer.com
international-journal-of-gynecological-cancer.com/article/S1048-891X(25)00793-5/fulltext18/#499 Mirvetuximab soravtansine and carboplatin for ...
MIRV and carbo demonstrated anti-tumor activity in patients with recurrent FRα-positive PSOC. MIRV 6 mg/kg AIBW and carbo AUC5 was selected as the phase 2 dose.
Safety and activity findings from a phase 1b escalation ...
These data demonstrate that mirvetuximab soravtansine combined with carboplatin is a well-tolerated and highly active regimen in recurrent, platinum-sensitive ...
A randomized phase II trial of mirvetuximab soravtansine ...
Preliminary data for the combination of MIRV with carboplatin exist from the Phase 1b FORWARD II trial, which resulted in an ORR of 71%, observed in 17 pts ...
Safety and activity findings from a phase 1b escalation ...
These data demonstrate that mirvetuximab soravtansine combined with carboplatin is a well-tolerated and highly active regimen in recurrent, platinum-sensitive ...
7.
gynecologiconcology-online.net
gynecologiconcology-online.net/article/S0090-8258(24)00071-4/fulltextPhase 1b study of mirvetuximab soravtansine, a folate ...
Evaluate the antitumor activity and safety profile of the triplet combination of mirvetuximab soravtansine (MIRV), carboplatin, and bevacizumab ...
Results From the SORAYA Study - ASCO Publications
MIRV demonstrated consistent clinically meaningful antitumor activity and favorable tolerability and safety in patients with FRα-high PROC who had received up ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.